



Contact:

David Waldman or Justyna Gudaszevska
Crescendo Communications Europe Sp. z o.o.
Email: mmd@crescendo-ir.com
Tel: + 48 71 79 11 551

Milestone Medical Inc. Provides Business Update Regarding Launch of New Medical Instruments

LIVINGSTON, NJ, February 26, 2015 -- Milestone Medical Inc. (WAR: MMD), today provided a business update on the status of its new medical instruments based on Milestone Scientific's computer-controlled injection and drug delivery technology. These new medical instruments represent alternatives to the syringe and are designed to provide cost reductions, safe, controlled painless injections.

Leonard Osser, Chief Executive Officer of Milestone Scientific, commented, "We are making progress in launching our new epidural and intra-articular ("IA") instruments. As previously disclosed, we have now received CE Mark marketing clearance for our epidural and IA instruments in Europe, which marks an important milestone. We are in the process of pursuing distribution agreements in Europe and anticipate finalizing the first of these arrangements in Europe over the coming months. We are also pleased to have announced important distribution agreements for our epidural and IA instruments in China. China represents a sizable market opportunity and these agreements contain minimum purchase requirements following CFDA marketing clearance, illustrating the confidence of our distribution partner. We plan to commence the CFDA marketing clearance process following FDA marketing clearance in the United States."

"In the U.S., a major U.S. distributor has been approved for our epidural instrument. Once we receive FDA marketing clearance, the guaranteed minimums will begin with immediate shipments. We are now in the process of commencing additional clinical trials, which we have confidence will go well, having previously conducted successful clinical trials on epidurals with our predicate instrument which has FDA approval. Our plan is to complete these new clinical studies in the second quarter of 2015. After a statistical analysis of the studies, we plan to return to the FDA for final marketing clearance. We also continue to advance the IA instrument; however it is difficult to accurately predict the exact timing as the regulatory process is outside of our control."

About Milestone Medical Inc.

Milestone Medical, Inc. has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by

Milestone Scientific, Inc. Development of both the epidural and intra-articular instruments is now complete and the Company is currently pursuing regulatory marketing clearance in the U.S. and China and has recently received CE marketing clearance for both instruments in the European Union. For more information please visit www.medicalmilestone.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

###